DIAGNOSTIC_TEST
ECHOCARDIOGRAPHY
A complete echocardiographic exam will be performed during each cardio-oncologic evaluation.
Cardiovascular Health in Adult Patients With Cancer Exposed to Cardiotoxic Therapies
Status
Recruiting
Phase
Not applicable
Enrollment
300
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The goal of this observational study is to evaluate the cardiovascular health and prognosis of adult patients with cancer, treated with cardiotoxic therapies. The main purposes of the study are the following: * Identify the demographic factors related to the onset of cardiotoxicity produced by anticancer drugs. * Identify any subgroups more likely to develop distant major adverse cardiovascular events (MACE). * Evaluate the usefulness of clinical, biohumoral and echocardiographic parameters for early diagnosis of cardiotoxicity. Participants will be monitored during the anticancer treatment via clinical, laboratory and instrumental evaluation according to the recommendation of the current guidelines on Cardio-Oncology (European Society of Cardiology, 2022). Initial follow-up will be 2 years.
Full detailed description
The goal of this observational study is to evaluate the cardiovascular health and prognosis of adult patients with cancer, exposed to potentially-cardiotoxic therapies. The main purposes of the study are the following: * Identify the demographic factors related to the onset of cardiotoxicity produced by anticancer drugs. * Identify any subgroups of patients more likely to develop distant major adverse cardiovascular events (MACE). * Evaluate the usefulness of clinical, bio-humoral and echocardiographic parameters for early diagnosis of cardiotoxicity. Participants will be monitored during the anticancer treatment via clinical, laboratory and instrumental evaluation according to the recommendations of the available guidelines on Cardio-Oncology (European Society of Cardiology, 2022). Initial follow-up will be 2 years.
Interventions
Treatment arms and agents.
DIAGNOSTIC_TEST
ELECTROCARDIOGRAPHY (ECG)
An ECG tracing will be obtained during each cardio-oncologic evaluation.
DIAGNOSTIC_TEST
LABORATORY TESTS
The cardiac biomarkers high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide (NT-proBNP) will be dosed according to the current recommendations of Cardio-Oncology Guidelines.
Timeline
From registration to results.
First posted
Oct 29, 2024
Study start
Feb 28, 2025
Primary completion
Nov 15, 2028
Study completion
Dec 15, 2028
Results posted
Not reported
Registry updated
Mar 4, 2025
Outcomes
What the study measures.
Primary outcomes
Incidence of cardiotoxicity
Time frame · 24 months
Incidence of cancer therapy-related cardiovascular toxicity according to the definitions of the European Society of Cardiology Cardio-Oncology Guidelines, published in 2022.
Identification of major cardiovascular adverse events (MACE)
Time frame · 24 months
Identification of cardiovascular death, non-cardiovascular death and hospitalization for cardiac causes (congestive heart failure, major arrhythmias) both during the antineoplastic treatments and in the long-survivors population.
Secondary outcomes
Identification of early predictors of cardiotoxicity
Time frame · 24 months
Identification of any anamnestic, clinical, electrocardiographic and echocardiographic predictors of cardiotoxicity or major cardiovascular adverse events (MACE) at follow-up.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Patients over the age of 18 at the time of evaluation * Patients treated with potentially cardiotoxic anticancer drugs * Patients for which complete clinical, electrocardiographic and echocardiographic data are available at first evaluation and at least at one follow-up visit. Exclusion Criteria: * Patients under the age of 18 at the time of evaluation * Patients whose documentation of the first visit is not available * Patients for whom it is not possible to obtain follow-up information through a medical visit or by telephone * Patient with poor acoustic window for echocardiographic examination. * Refusal of informed consent to participate in the study.
Study locations
1 registered sites.
Italy. Showing up to 24 locations stored in the fast local snapshot.
Fondazione Policlinico Universitario A. Gemelli IRCCS;UOSD diagnostica cardiologica non invasiva
Rome, Lazio, Italy
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Nesiritide.
NCT IDStudyPhase / statusEnrollmentUpdated
PRIMARY-HF: Heart Failure Screening in Primary Care Using Point-of- Care
Universidade do Porto · Heart Failure
Not applicable
Recruiting
160
2026-07
Boston Medical Center Ultrasound Decongestion Study in Heart Failure
Boston Medical Center · Congestive Heart Failure · Volume Overload
Not applicable
Not yet recruiting
200
2026-06
Measurement Of NT-proBNP to Predict Outcomes in Surgery
Norfolk and Norwich University Hospitals NHS Foundation Trust · Vascular Surgical Procedure
Not applicable
Recruiting
200
2026-06
rhBNP for Prevention of Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI)
China National Center for Cardiovascular Diseases · AKI - Acute Kidney Injury · Cardiac Surgical Procedures
Phase 4
Not yet recruiting
694
2026-06
Utilising AI Analysis of Sounds To prEdict heaRt failurE decOmpensation
Cambridge University Hospitals NHS Foundation Trust · Heart Failure
Not applicable
Recruiting
250
2026-05
Venous Excess and Lung Ultrasound During Continuous Kidney Replacement Therapy in Critically Ill Patients
Chulalongkorn University · Acute Kidney Failure Stage 3
Not applicable
Completed
100
2026-05
Spironolactone Therapy in Chronic Stable Right HF Trial
Ottawa Heart Institute Research Corporation · Chronic Right-Sided Heart Failure · Pulmonary Arterial Hypertension
Phase 4
Completed
15
2026-05
Secondary Use of PARALLEL-HF Data
Novartis · Chronic Heart Failure and Reduced Ejection Fraction (HFrEF)
Not applicable
Completed
236
2026-04
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.